Oral semaglutide vs. oral Wegovy: which pill is which?

"Oral semaglutide" means any semaglutide you swallow rather than inject. Three kinds are sold in the US, and they are not interchangeable.

• Wegovy pill. 25 mg once daily, reached after 30 days each at 1.5 mg, 4 mg and 9 mg. Approved for adults with obesity, or overweight with a weight-related condition. Also approved to lower major cardiovascular events in adults with heart disease and excess weight.
• Ozempic pill and Rybelsus. 1.5, 4 and 9 mg (Ozempic pill) or 3, 7 and 14 mg (Rybelsus), for adults with type 2 diabetes. The tablets also hold a heart-risk indication for high-risk adults with diabetes. Novo Nordisk began moving US patients to the Ozempic pill in May 2026.
• Compounded oral semaglutide. Made by a pharmacy at strengths it chooses. Not FDA-approved, not a generic, and with no trials of its own.

One detail causes confusion. The Wegovy pill and the Ozempic pill share the 1.5, 4 and 9 mg tablet strengths during titration. Their labels, their uses and their top doses are still different.

Oral Wegovy has not been tested head to head against the diabetes tablets. Their trials answered different questions.

OASIS 4 (NEJM, 2025) is the Wegovy pill's pivotal trial. It enrolled 307 adults with obesity or overweight, randomized to 25 mg daily or placebo for 64 weeks. Mean weight change was −13.6% on the tablet and −2.2% on placebo across all participants. Novo Nordisk reports about 16.6% among people who stayed on treatment, and roughly one in three losing 20% or more. The Wegovy label also lists cardiovascular risk reduction for the tablet.

PIONEER 4 (Lancet, 2019) is one of the trials behind the diabetes tablet. At 14 mg, HbA1c fell 1.2 percentage points at 26 weeks, with more weight loss than liraglutide injection. SOUL (NEJM, 2025) followed 9,650 adults with type 2 diabetes and high cardiovascular risk. Oral semaglutide up to 14 mg cut major cardiovascular events by 14% versus placebo.

The top doses differ: 25 mg for the Wegovy pill against 9 mg for the Ozempic pill. The diabetes tablets were not designed or tested as weight-loss treatments.

Compounded tablets have no published trials. The absorption shown for the SNAC-based branded tablets cannot be assumed for a different pharmacy formulation.

All three types share semaglutide's profile. Gut symptoms come first: nausea, vomiting, diarrhea, constipation and belly pain. They peak during titration, which is one reason the Wegovy pill takes 90 days to reach 25 mg.

The prescribing information for Rybelsus and the Ozempic pill reports nausea in 20% of people at 14 mg and vomiting in 8%. The Wegovy label flags dysesthesia, a tingling or burning skin sensation, with its tablet as well as its injection, more often at higher doses.

Some cautions apply to every semaglutide tablet. A label study found thyroid hormone exposure rose by a third when levothyroxine was taken alongside. Slower stomach emptying can affect other oral drugs too. The labels also advise against breastfeeding while taking semaglutide tablets.

Serious risks are uncommon but shared: pancreatitis, gallbladder disease, kidney injury from dehydration, diabetic retinopathy complications, and low blood sugar when combined with insulin or a sulfonylurea. Every approved oral semaglutide carries the boxed warning on thyroid C-cell tumors in rodents.

Pick by the reason for treatment first, then by product.

For weight management, the Wegovy pill is the only approved oral option. It fits adults with obesity, or with overweight plus a condition such as high blood pressure, who prefer a tablet and can keep a fasting morning routine. Teenagers are not covered by the pill; the Wegovy injection is approved from age 12.

For type 2 diabetes, the Ozempic pill is the approved oral choice, with Rybelsus being phased out. It is not a cheaper stand-in for weight treatment. Its top dose is lower, and its label is diabetes-only.

Compounded oral semaglutide is what some people turn to when brand tablets are unaffordable. The useful questions are about the product rather than the molecule. What strength is it? Does it contain an absorption enhancer? What instructions does the pharmacy give?

No oral semaglutide suits people with severe gastroparesis, or anyone with a personal or family history of medullary thyroid carcinoma or MEN 2. If your mornings cannot absorb a 30-minute wait, a weekly injection may be the better fit.